# US 2022/0031806 A1 · Cd80 extracellular domain fc fusion proteins for treating pd-l1 negative tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031806 A1
- Document ID: US20220031806A1
- Status: Published application
- Kind: A1
- Application number: 17/432,640
- Filed: 2020-02-21
- Published: 2022-02-03
- Earliest claimed: 2019-02-22
- Assignees: Five Prime Therapeutics, Inc.
- Applicants: Five Prime Therapeutics, Inc.
- Inventors: Susannah D. BARBEE; Thomas BRENNAN; Barbara SENNINO
- Web page: https://patentgrep.com/patent/US20220031806A1

## CPC

- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61P 35/00: Antineoplastic agents
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2333/70532: B7 molecules, e.g. CD80, CD86
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides methods of treating PD-L1 negative tumors, the methods comprising administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1).

## Claims

### Claim 1

A method of treating a PD-L1 negative tumor in a subject, the method comprising administering to the subject a composition comprising CD80 extracellular domain (ECD) fusion molecules.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tumor has been determined to be PD-L1 negative prior to the administration.

### Claim 3 (depends on 1)

The method of claim 1, further comprising determining that the tumor is PD-L1 negative prior to the administration.

### Claim 4

A method of selecting a subject with a tumor for treatment with a composition comprising CD80 ECD fusion molecules, the method comprising determining whether a tumor sample obtained from the subject is PD-L1 negative and selecting the subject for treatment with the composition if the tumor sample is determined to be PD-L1 negative.

### Claim 5

A composition comprising CD80 ECD fusion molecules for use in the treatment of a PD-L1 negative cancer tumor in a subject.

### Claim 6 (depends on 5)

The composition for use of claim 5, wherein the subject is selected for the treatment by determining that a tumor sample obtained from the subject is PD-L1 negative.

### Claim 7

A composition comprising CD80 ECD fusion molecules for use in the treatment of a tumor in a subject, wherein the tumor has been determined to be PD-L1 negative.

### Claim 8

An in vitro method for identifying a subject with a tumor that is responsive to treatment with a composition comprising CD80 ECD fusion molecules, the method comprising determining whether a tumor sample obtained from the subject is PD-L1 negative, wherein the subject is identified as being responsive to treatment with a CD80 ECD fusion molecule if the tumor sample is determined to be PD-L1 negative.

### Claim 9

An in vitro use of at least one agent capable of determining that a tumor sample is PD-L1 negative, for identifying a subject with a tumor that is responsive to treatment with a composition comprising CD80 ECD fusion molecules.

### Claim 10 (depends on 2, 3, 4)

The method, composition, or use of any one of claims 2-4, and 6-9, wherein the tumor has been determined or is determined to be PD-L1 negative using an agent that is capable of detecting PD-L1 protein, optionally wherein the agent is an antibody that specifically binds to PD-L1 protein.

### Claim 11 (depends on 10)

The method, composition, or use of claim 10, wherein the tumor has been determined or is determined to be PD-L1 negative by Western blot.

### Claim 12 (depends on 10)

The method, composition, or use of claim 10, wherein the tumor has been determined or is determined to be PD-L1 negative by fluorescence-activated cell sorting (FACS).

### Claim 13 (depends on 10)

The method, composition, or use of claim 10, wherein the tumor has been determined or is determined to be PD-L1 negative by immunohistochemistry (IHC), optionally wherein the sample is a paraffin-embedded sample.

### Claim 14 (depends on 2, 3, 4, 6, 7, 8, 9)

The method, composition, or use of any one of claims 2-4 and 6-9, wherein the tumor has been determined or is determined to be PD-L1 negative using an agent that is capable of detecting PD-L1 mRNA.

### Claim 15 (depends on 14)

The method, composition, or use of claim 14, wherein the tumor has been determined or is determined to be PD-L1 negative by quantitative reverse transcriptase (RT)-polymerase chain reaction (PCR).

### Claim 16 (depends on 14)

The method, composition, or use of claim 14, wherein the tumor has been determined or is determined to be PD-L1 negative using RNA-Seq.

### Claim 17 (depends on 14)

The method, composition, or use of claim 14, wherein the tumor has been determined or is determined to be PD-L1 negative using a microarray.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method, composition, or use of any one of claims 1-17, wherein the tumor is a solid tumor.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method, composition, or use of any one of claims 1-18, wherein the subject is afflicted with a cancer selected from the group consisting of colorectal cancer, breast cancer, gastric cancer, non-small cell lung cancer, melanoma, squamous cell carcinoma of the head and neck, ovarian cancer, pancreatic cancer, renal cell carcinoma, hepatocellular carcinoma, bladder cancer, and endometrial cancer.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method, composition, or use of any one of claims 1-19, wherein the subject is afflicted with a cancer that is recurrent or progressive after a therapy consisting of surgery, chemotherapy, radiation therapy, or a combination thereof.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method, composition, or use of any one of claims 1-20, wherein the CD80 ECD fusion molecules comprise a human CD80 ECD and a human IgG1 Fc domain.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method, composition, or use of any one of claims 1-21, wherein the composition comprises sialylated CD80 ECD fusion molecules.

### Claim 23 (depends on 22)

The method, composition, or use of claim 22, wherein the sialylated CD80 ECD fusion molecules comprise at least 15 moles of sialic acid (SA) per mole of fusion protein.

### Claim 24 (depends on 22)

The method, composition, or use of claim 22, wherein the sialylated CD80 ECD fusion molecules comprise 15-60 moles of SA per mole of fusion protein.

### Claim 25 (depends on 22)

The method, composition, or use of claim 22, wherein the sialylated CD80 ECD fusion molecules comprise 15-40 moles of SA per mole of fusion protein.

### Claim 26 (depends on 22)

The method, composition, or use of claim 22, wherein the sialylated CD80 ECD fusion molecules comprise 15-30 moles of SA per mole of fusion protein.

### Claim 27 (depends on 22)

The method, composition, or use of claim 22, wherein the sialylated CD80 ECD fusion molecules comprise 20-30 moles of SA per mole of fusion protein.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method, composition, or use of any one of claims 1-27, wherein the CD80 ECD fusion molecules comprise a human CD80 ECD comprising the amino acid sequence of SEQ ID NO:1.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method, composition, or use of any one of claims 1-28, wherein the CD80 ECD fusion molecules comprise a human IgG1 Fc domain comprising the amino acid sequence of SEQ ID NO:3.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method, composition, or use of any one of claims 1-29, wherein the Fc domain of human IgG1 is linked to the carboxy terminus of the ECD of human CD80.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method, composition, or use of any one of claims 1-30, wherein the CD80 ECD fusion molecules comprise the amino acid sequence of SEQ ID NO:5.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method, composition, or use of any one of claims 1-31, wherein the PD-L1 negative tumor has a TPS score of less than 5% or less than 1%.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method, composition, or use of any one of claims 1-32, wherein the composition alone does not cause significant release of interferon gamma or TNF alpha from T-cells in vitro.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method, composition, or use of any one of claims 1-33, wherein the composition alone causes less release of interferon gamma or TNF alpha from T-cells in vitro than TGN1412 alone.

### Claim 35 (depends on 34)

The method, composition, or use of claim 34, wherein the composition alone is at least 1000-fold less potent at inducing interferon gamma or TNF alpha release compared to TGN1412 alone.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method, composition, or use of any one of claims 1-35, wherein the composition is capable of at least 90% tumor growth inhibition in at least one mouse syngeneic cancer model over a period of at least one week, 10 days, two weeks, or three weeks following administration of a single dose of the composition at 0.3 to 0.6 mg/kg.

### Claim 37 (depends on 36)

The method, composition, or use of claim 36, wherein the mouse syngeneic cancer model is a CT26 tumor model.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method, composition, or use of any one of claims 1-37, wherein the treatment comprises administration of about 0.07 mg to about 70 mg of the CD80 ECD fusion molecules.

### Claim 39 (depends on 38)

The method, composition, or use of claim 38, wherein the treatment comprises administration of about 7.0 mg to about 70 mg of the CD80 ECD fusion molecules.

### Claim 40 (depends on 39)

The method, composition, or use of claim 39, wherein the treatment comprises administration of about 70 mg of the CD80 ECD fusion molecules.

### Claim 41 (depends on 39)

The method, composition, or use of claim 39, wherein the treatment comprises administration of about 42 mg of the CD80 ECD fusion molecules.

### Claim 42 (depends on 39)

The method, composition, or use of claim 39, wherein the treatment comprises administration of about 21 mg of the CD80 ECD fusion molecules.

### Claim 43 (depends on 39)

The method, composition, or use of claim 39, wherein the treatment comprises administration of about 7 mg of the CD80 ECD fusion molecules.

### Claim 44 (depends on 38)

The method, composition, or use of claim 38, wherein the treatment comprises administration of about 2.1 mg of the CD80 ECD fusion molecules.

### Claim 45 (depends on 38)

The method, composition, or use of claim 38, wherein the treatment comprises administration of about 0.7 mg of the CD80 ECD fusion molecules.

### Claim 46 (depends on 38)

The method, composition, or use of claim 38, wherein the treatment comprises administration of about 0.21 mg of the CD80 ECD fusion molecules.

### Claim 47 (depends on 38)

The method, composition, or use of claim 38, wherein the treatment comprises administration of about 0.07 mg of the CD80 ECD fusion molecules.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method, composition, or use of any one of claims 1-47, wherein the treatment comprises administration once every three weeks.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method, composition, or use of any one of claims 1-48, wherein the treatment comprises intravenous administration of the CD80 ECD fusion molecules.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method, composition, or use of any one of claims 1-49, wherein the subject has not received prior therapy with a PD-1/PD-L1 antagonist.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method, composition, or use of any one of claims 1-50, wherein the subject has received prior therapy with at least one anti-angiogenic agent.

### Claim 52 (depends on 51)

The method, composition, or use of claim 51, wherein the anti-angiogenic agent is sunitinib, sorafenib, pazopanib, axitinib, tivozanib, ramucirumab, or bevacizumab.

### Claim 53 (depends on 51, 52)

The method, composition, or use of claim 51 or 52, wherein the anti-angiogenic agent was administered in an advanced or metastatic setting.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method, composition, or use of any one of claims 1-53, wherein the subject is afflicted with a melanoma that has a BRAF mutation.

### Claim 55 (depends on 54)

The method, composition, or use of claim 54, wherein the subject has received prior therapy with at least one BRAF inhibitor.

### Claim 56 (depends on 55)

The method, composition, or use of claim 55, wherein the BRAF inhibitor is vemurafenib or dabrafenib.

### Claim 57 (depends on 55, 56)

The method, composition, or use of claim 55 or 56, wherein the BRAF inhibitor was administered in an advanced or metastatic setting.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method, composition, or use of any one of claims 1-57, wherein the tumor is recurrent or progressive after a therapy selected from surgery, chemotherapy, radiation therapy, and a combination thereof

### Claim 59

A method of treating a PD-L1 negative tumor in a human patient, the method comprising administering to the patient a composition comprising about 0.07 mg to about 70 mg CD80 extracellular domain (ECD) fusion molecules comprising the amino acid sequence of SEQ ID NO:5.

### Claim 60 (depends on 59)

The method of claim 59, wherein the tumor has been determined to be PD-L1 negative by IHC prior to the administration.

### Claim 61 (depends on 59, 60)

The method of claim 59 or 60, wherein the composition comprises sialylated CD80 ECD fusion molecules and wherein the sialylated CD80 ECD fusion molecules comprise 15-60 moles of SA per mole of fusion protein.
